<DOC>
	<DOCNO>NCT01943786</DOCNO>
	<brief_summary>Adenocarcinoma colon rectum common , serious disease second cause death cancer Spain . The prognosis CRC depend great extent stage diagnose . Patients advanced disease , present 40 % patient , poor prognosis . Although application modern chemotherapy radiotherapy treatment obtain median survival period around 24 month , proportion patient advanced disease obtain cure low . Systemic treatment advance CRC change considerably last ten year introduction active drug oxaliplatin , irinotecan , capecitabine . The commonly use first line regimens 5-Fluorouracil-Leucovorin-Oxaliplatin ( FOLFOX ) , Capecitabine-Oxaliplatin ( XELOX ) , 5-Fluorouracil-Leucovorin-Irinotecan ( FOLFIRI ) , less extent , Capecitabine-Irinotecan ( XELIRI ) . Chemotherapy regimens combine different agent therapeutic target , three effective colon cancer : bevacizumab , target vascular endothelial growth factor ( VEGF ) cetuximab panitumumab , target epidermal growth factor receptor ( EGFR ) . The use cetuximab panitumumab recommend patient KRAS mutation combination VEGF EGFR agent beneficial . Two recent study result identify KRAS mutation frequent driver acquire resistance cetuximab panitumumab colorectal cancer patient . The conclusion indicate emergence KRAS mutant clone detect non-invasively month radiographic progression DNA Blood Test ( Inostics´BEAMing Technology ) . Centro Integral Oncológico Clara Campal ( CIOCC ) aim undertake pioneer project aim integrating analysis KRAS switch status BEAMing Technology patient metastatic colorectal cancer , tumor KRAS wild-type BEAMing wild-type treat first line FOLFIRI-cetuximab In naive chemotherapy tumor-KRAS wild-type metastatic colorectal cancer patient , BEAMing positive ( KRAS mutate blood ) treatment may worse evolution term PFS ( progression Free Survival ) response rate BEAMing negative ( KRAS native blood ) patient . To know proportion patient BEAMing positive ( KRAS mutation detect circulate extracellular DNA ) begin treatment , could great importance treatment efficacy .</brief_summary>
	<brief_title>RAS Switch Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Diagnosis stage IV colorectal adenocarcinoma . Patient ≥ 18 year age . ECOG PS 01 Life expectancy ≥ 6 month Candidate firstline systemic chemotherapy accord regular clinical practice . Measurable disease . Wildtype KRAS Signed informed consent form . Patient receive prior chemotherapy metastatic CRC , except adjuvant treatment complete least six month enter study . Patient contraindication use drug use firstline treatment colorectal cancer : 5fluorouracil , , irinotecan cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Wild type KRAS</keyword>
</DOC>